To the Editor: Marginal zone lymphoma (MZL) is an indolent B-cell malignancy characterized by protracted clinical courses, frequent relapses, and significant biological heterogeneity. The current frontline standard of care relies heavily on rituximab-based immunochemotherapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Luya
Contact Luya, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack